Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.
BACKGROUND
HIV-1 typically develops resistance to any single antiretroviral agent. Combined anti-retroviral therapy to reduce drug-resistance development is necessary to control HIV-1 infection. Here, to assess the utility of a combination of antibody and fusion inhibitor treatments, we investigated the potency of monoclonal antibodies at neutralizing HIV-1 variants that are resistant to fusion inhibitors.


RESULTS
Mutations that confer resistance to four fusion inhibitors, enfuvirtide, C34, SC34, and SC34EK, were introduced into the envelope of HIV-1JR-FL, a CCR5-tropic tier 2 strain. Pseudoviruses with these mutations were prepared and used for the assessment of neutralization sensitivity to an array of antibodies. The resulting neutralization data indicate that the potencies of some antibodies, especially of those against the CD4 binding site, V3 loop, and membrane-proximal external region epitopes, were increased by the mutations in gp41 that conferred resistance to the fusion inhibitors. C34-, SC34-, and SC34EK-resistant mutants showed more sensitivity to monoclonal antibodies than enfuvirtide-resistant mutants. An analysis of C34-resistant mutations revealed that the I37K mutation in gp41 HR1 is a key mutation for C34 resistance, low infectivity, neutralization sensitivity, epitope exposure, and slow fusion kinetics. The N126K mutation in the gp41 HR2 domain contributed to C34 resistance and neutralization sensitivity to anti-CD4 binding site antibodies. In the absence of L204I, the effect of N126K was antagonistic to that of I37K. The results of a molecular dynamic simulation of the envelope trimer confirmation suggest that an I37K mutation induces the augmentation of structural fluctuations prominently in the interface between gp41 and gp120. Our observations indicate that the "conformational unmasking" of envelope glycoprotein by an I37K mutation is one of the mechanisms of neutralization sensitivity enhancement. Furthermore, the enhanced neutralization of C34-resistant mutants in vivo was shown by its high rate of neutralization by IgG from HIV patient samples.


CONCLUSIONS
Mutations in gp41 that confer fusion inhibitor resistance exert enhanced sensitivity to broad neutralizing antibodies (e.g., VRC01 and 10E8) and other conventional antibodies developed in HIV-1 infected patients. Therefore, next-generation fusion inhibitors and monoclonal antibodies could be a potential combination for future regimens of combined antiretroviral therapy.
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Muntasir
M
Alam
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Takeo
T
Kuwata
Laboratory of Virus Control, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Kazuya
K
Shimura
Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan.
Masaru
M
Yokoyama
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Kristel Paola
KP
Ramirez Valdez
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Kazuki
K
Tanaka
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Yasuhiro
Y
Maruta
Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Shinya
S
Oishi
Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Nobutaka
N
Fujii
Pathogen Genomics Center, National Institute of Infectious Diseases, Tokyo, Japan.
Hironori
H
Sato
Laboratory of Virus Control, Institute for Virus Research, Kyoto University, Kyoto, Japan.
Masao
M
Matsuoka
Matsushita Project Laboratory, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan. shuzo@kumamoto-u.ac.jp.
Shuzo
S
Matsushita
Fusion inhibitor resistance; HIV; Neutralization sensitivity
AIDS. 2015 Feb 20;29(4):453-62
25630040
AIDS. 2006 Oct 24;20(16):2065-73
17053352
J Antimicrob Chemother. 2006 Oct;58(4):714-22
16891628
Nat Rev Immunol. 2012 Jul 20;12(8):607-14
22814509
J Virol. 2007 Apr;81(8):3757-68
17251298
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5318-23
19289833
J Virol. 2010 Aug;84(15):7558-68
20504942
J Virol. 1996 Feb;70(2):1100-8
8551569
Front Microbiol. 2016 Feb 09;7:110
26903989
J Virol. 2009 Apr;83(7):2989-95
19153234
Top Antivir Med. 2015 Oct-Nov;23(4):132-41
26713503
Lancet. 2006 Aug 5;368(9534):466-75
16890833
Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5972-7
20231447
N Engl J Med. 2008 Oct 2;359(14):1442-55
18832245
J Virol. 2003 May;77(10):5863-76
12719580
Antiviral Res. 2013 Apr;98(1):93-120
23403210
Curr Opin Virol. 2013 Feb;3(1):51-7
23290628
J Virol. 2014 Feb;88(3):1795-808
24284318
J Virol. 2008 Dec;82(24):12449-63
18842730
PLoS One. 2008 Sep 12;3(9):e3206
18787705
J Virol. 2005 Oct;79(19):12455-63
16160173
PLoS One. 2013 Jun 28;8(6):e65115
23840315
Nature. 2015 Jun 25;522(7557):487-91
25855300
J Virol. 2015 Oct 21;90(2):636-49
26491157
J Virol. 2013 May;87(10):5424-36
23468483
Viruses. 2012 Dec;4(12):3859-911
23342377
Virology. 2007 Dec 20;369(2):245-62
17825343
AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65
11788027
Angew Chem Int Ed Engl. 2002 Aug 16;41(16):2937-40
12203417
Nature. 2012 Nov 15;491(7424):406-12
23151583
J Immunol. 1994 Aug 15;153(4):1895-904
7519220
J Immunol Methods. 2014 Jul;409:131-46
24291345
PLoS One. 2012;7(5):e37530
22624045
Int J Biochem Cell Biol. 2009 Apr;41(4):891-9
18834950
J Virol. 2005 Apr;79(8):4991-9
15795284
Curr Opin Virol. 2016 Jun;18:50-6
27023283
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54
12444251
J Virol. 2005 Oct;79(19):12447-54
16160172
Nature. 2014 Oct 23;514(7523):455-61
25296255
Nature. 2013 Nov 14;503(7475):224-8
24172905
J Virol. 2008 Dec;82(24):12585-8
18842727
Methods Mol Biol. 2009;485:395-405
19020839
J Biol Chem. 2010 Dec 10;285(50):39471-80
20937812
Virology. 2005 Jul 20;338(1):154-72
15932765
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1166-71
20080564
Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7
26841901
Antiviral Res. 2013 May;98(2):158-70
23541872
Lancet. 2007 Apr 7;369(9568):1169-78
17416261
Science. 2016 May 20;352(6288):1001-4
27199430
J Virol. 2013 Dec;87(24):13239-51
24067980
Front Microbiol. 2013 May 14;4:117
23717307
Microbiol Spectr. 2015 Feb;3(1):AID-0025-2014
26104552
Curr Protoc Cell Biol. 2011 Mar;Chapter 26:Unit 26.9
21400700
PLoS Pathog. 2012;8(7):e1002797
22807678
Curr Opin HIV AIDS. 2009 Mar;4(2):150-8
19339955
Front Microbiol. 2012 Jul 19;3:258
22833741
Sci Transl Med. 2015 Dec 23;7(319):319ra206
26702094
EMBO Rep. 2008 Feb;9(2):144-50
18246106
J Virol. 2012 Nov;86(22):12105-14
22933284
J Virol. 2005 Jan;79(2):764-70
15613304
J Virol. 2010 Mar;84(6):2955-62
20042512
Virology. 2015 Jan 15;475:187-203
25486586
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6679-85
15870208
Lancet Infect Dis. 2016 May;16(5):565-575
26831472
J Virol. 2014 Jan;88(2):1249-58
24227838
J Pharmacol Toxicol Methods. 2005 May-Jun;51(3):187-200
15862464
Science. 2014 Nov 7;346(6210):759-63
25298114
J Exp Med. 2011 Mar 14;208(3):439-54
21357743
AIDS Res Hum Retroviruses. 2009 Jul;25(7):701-5
19552592
Lancet Infect Dis. 2016 May;16(5):512-513
26831126
J Virol. 2004 Jul;78(13):6775-85
15194752
Proteins. 2010 Jun;78(8):1950-8
20408171
Nature. 2012 Dec 6;492(7427):118-22
23103874
J Virol. 2004 May;78(10):5476-85
15113926
PLoS Pathog. 2015 Jan 08;11(1):e1004595
25569556
J Virol. 2006 Mar;80(5):2405-17
16474147